A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
36actual
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-16 | actual | When the study began enrolling |
| Primary completion | 2026-04-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-08 | actual | The whole study's end, after follow-up |
| First posted | 2025-12-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 1
Intervention
- Drug: NNC0363-1063
Primary outcome
what the primary-completion date above is the date OFAUC, GIR,SS: Area under the glucose infusion rate-time curve at steady state
measured Visit 2 and 3: Day 2 and 3
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed